<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00484120</url>
  </required_header>
  <id_info>
    <org_study_id>PH-2007-2</org_study_id>
    <nct_id>NCT00484120</nct_id>
  </id_info>
  <brief_title>Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for Knee OA Pain</brief_title>
  <official_title>Proof-of Concept Study to Evaluate the Safety and Analgesic Efficacy of Topical 3%-Diclofenac-Nano-Emulsion Cream Versus Placebo for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study valuates the safety and efficacy of treatment with 3% Diclofenac Nano-Emulsion&#xD;
      Cream versus Placebo in subjects with osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, double-blind, placebo-controlled, multiple-dose, parallel&#xD;
      treatment study. A total of 126 subjects will be randomized to receive either&#xD;
      3%-Diclofenac-NE cream or a placebo cream respectively. Following screening and a washout&#xD;
      period from previous treatments subjects will be enrolled and will self-apply the study&#xD;
      medication. During the study, subjects will apply 3%-Diclofenac-NE or placebo cream three&#xD;
      times daily for 28 days and complete a home-diary. Subjects will visit the clinic at&#xD;
      mid-treatment for a follow up examination and again for a final examination at the end of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic activity as measured by the WOMAC pain subscale.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient's daily pain assessment in the home diary.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on walking.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3% Diclofenac NE cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3%-Diclofenac-Nano-Emulsion Cream</intervention_name>
    <description>3%-Diclofenac-Nano-Emulsion Cream</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>Placebo cream</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 50 years of age and above.&#xD;
&#xD;
          2. Patients with primary osteoarthritis in at least a single knee joint, grade 2 or 3&#xD;
             based on the Kellgren and Lawrence classification system.&#xD;
&#xD;
          3. Radiographic evidence consistent with OA carried out within the 6 months before&#xD;
             screening.&#xD;
&#xD;
          4. Pain should have been present for at least half of the days in the previous month and&#xD;
             for at least 48h prior to the screening visit.&#xD;
&#xD;
          5. Eligible subjects must have used an oral, topical or rectal NSAID within the past 6&#xD;
             months before screening.&#xD;
&#xD;
          6. At baseline, after a 1 week withdrawal period of analgesic/anti-inflammatory&#xD;
             medications, subjects should have a flare of pain.&#xD;
&#xD;
          7. Able to read, comprehend, and sign the consent form.&#xD;
&#xD;
          8. Examined by the authorized physician and medically cleared to participate in the&#xD;
             study.&#xD;
&#xD;
          9. In general good health and have no contraindications to any of the investigational&#xD;
             medicinal products.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary osteoarthritis.&#xD;
&#xD;
          2. Presence of a serious or unstable medical condition (e.g., malignancy, severe&#xD;
             neurological impairment or uncontrolled hypertension) or poor general health&#xD;
             interfering with compliance or assessment at the study physician's discretion.&#xD;
&#xD;
          3. OA causing significant pain in any joint other than the knees.&#xD;
&#xD;
          4. Any other rheumatic or non-rheumatic joint disease or any other painful condition&#xD;
             within the past month (e.g. fibromyalgia).&#xD;
&#xD;
          5. Knee surgery or other knee trauma at any time during the previous year or subjects for&#xD;
             whom a treatment is planned within the study period that could alter the degree or&#xD;
             nature of pain (e.g. arthroscopic techniques, osteotomy, joint replacement surgery&#xD;
             etc.).&#xD;
&#xD;
          6. Active or history of gastrointestinal ulceration or bleeding within the past 5 years.&#xD;
&#xD;
          7. Presence of a significant active psychiatric disorder including major depression or&#xD;
             subjects receiving anti-psychotic medication.&#xD;
&#xD;
          8. Existence of any dermatological condition on the knee.&#xD;
&#xD;
          9. Subjects with disabling congestive heart failure (CHF), angina, pulmonary disease.&#xD;
&#xD;
         10. Clinically significant abnormal blood results.&#xD;
&#xD;
         11. Subjects cannot have had an arthrocentesis prior or during the study.&#xD;
&#xD;
         12. Concomitant treatment with physical and/or occupational therapy.&#xD;
&#xD;
         13. Prior use of any type of NSAID or other analgesic before taking the first dose of&#xD;
             investigational medicinal product. Rescue treatment will be allowed during the study&#xD;
&#xD;
         14. Change in sedative or CNS/psychotropic agent within the past month.&#xD;
&#xD;
         15. Chronic treatment with anticoagulants (e.g. Warfarin).&#xD;
&#xD;
         16. Subjects under treatment with corticosteroids.&#xD;
&#xD;
         17. Subjects using topical analgesics including OTC products.&#xD;
&#xD;
         18. Females who are pregnant, lactating, of child-bearing potential, or post-menopausal&#xD;
             for less than 2 years and not using a medically approved method of contraception&#xD;
             (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm,&#xD;
             condom, abstinence, or surgical sterility), or females who test positive on a&#xD;
             urine-based pregnancy test.&#xD;
&#xD;
         19. Active alcoholism or substance abuse.&#xD;
&#xD;
         20. Has taken an investigational drug or has used an investigational device within the&#xD;
             past 30 days.&#xD;
&#xD;
         21. History of hypersensitivity and/or idiosyncrasy to diclofenac or excipients employed&#xD;
             in this study, aspirin or other NSAIDS.&#xD;
&#xD;
         22. Has previously been entered into this study.&#xD;
&#xD;
         23. Any condition that in the investigator's judgement precludes participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eisenberg Elon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>9602</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>June 7, 2007</study_first_submitted>
  <study_first_submitted_qc>June 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2007</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Team</name_title>
    <organization>Pharmos Ltd</organization>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>Nano-emulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

